



www.hdfcfund.com

HDFC Asset Management Company Limited

A Joint Venture with Standard Life Investments

CIN: U65991MH1999PLC123027

Registered Office: HDFC House, 2nd Floor, H.T. Parekh Marg, 165-166, Backbay Reclamation, Churchgate, Mumbai - 400 020. Phone: 022 66316333 • Toll Free Nos: 1800-3010-6767 / 1800-419-7676
Fax: 022 22821144 • e-mail: cliser@hdfcfund.com • Visit us at: www.hdfcfund.com

NOTICE

NOTICE is hereby given that HDFC Trustee Company Limited, the Trustee to HDFC Mutual Fund has approved the declaration of dividend in **HDFC Debt Fund for Cancer Cure 2014**, a 3 year Close ended Capital Protection Oriented Income Scheme as given below:

Name of the Scheme / Plan / Option	NAV as on March 16, 2017 (₹ per unit)	Amount of Dividend (₹ per unit)	Impact of Dividend Distribution on NAV (₹ per unit)	Record Date	Face Value (₹ per unit)
HDFC Debt Fund for Cancer Cure 2014 – Regular Option	10.3868	Entire Distributable surplus, as reduced by applicable statutory levy	Distributable surplus	Thursday, March 23, 2017*	10.00
HDFC Debt Fund for Cancer Cure 2014 – Direct Option	10.3868				

*or the immediately following Business Day, if that day is not a Business Day.

Pursuant to payment of dividend, the NAV of the Dividend Option(s) of the above Scheme would fall to the extent of payout and statutory levy, if any.

Income distribution will be done / Dividend will be paid to those Unit holders / Beneficial Owners whose names appear in the register of Unit holders maintained by the Mutual Fund / statement of beneficial ownership maintained by the Depositories, as applicable, under the Dividend Option(s) of the aforesaid Scheme as on the Record Date.

Intimation of any change of address / bank details should be immediately forwarded to the Investor Service Centres of HDFC Mutual Fund (for units held in non-demat form) / Depository Participant (for units held in demat form).

For **HDFC Asset Management Company Limited**

Place : Mumbai
Date : March 17, 2017

Sd/-
Chief Compliance Officer

MUTUAL FUND INVESTMENTS ARE SUBJECT TO MARKET RISKS, READ ALL SCHEME RELATED DOCUMENTS CAREFULLY.